Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291733
Status:
UNKNOWN
Last Update Posted:
2007-11-15
First Post:
2006-02-14
Brief Title:
Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinsons Disease
Sponsor:
1st Hospital of Social Security Services
Organization:
1st Hospital of Social Security Services
Study Overview
Official Title:
Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinsons Disease A Double-BlindPlacebo-Controlled Crossover Trial
Status:
UNKNOWN
Status Verified Date:
2007-11
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Levodopa-induced dyskinesias have been associated with irregular oscillatory discharge characteristics of basal ganglia From the other hand LEV which shares a different electrophysiologic profile than other antiepileptics inhibits hyper-synchronization of abnormal neuronal firing in experimental models of epilepsy LEV also reduces levodopa-induced dyskinesias in MPTP-lesioned macaques and modulates priming phenomenon which associated with long-term changes in synaptic function that can lead to dyskinesias in PD
Study objectives
To evaluate the effects of levetiracetam LEV in two doses 500 and 1000mg vs placebo on disabling dyskinesias that develop as result of long-term treatment with levodopa occurring at the time of maximal clinical improvement in patients with Parkinsons disease PD
To evaluate the safety of LEV in patients with PD and antiparkinsonian medication
Study objectives
To evaluate the effects of levetiracetam LEV in two doses 500 and 1000mg vs placebo on disabling dyskinesias that develop as result of long-term treatment with levodopa occurring at the time of maximal clinical improvement in patients with Parkinsons disease PD
To evaluate the safety of LEV in patients with PD and antiparkinsonian medication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None